# EU-1-13-891_public-assessment-report_20140114_20140114_brintellix-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE
MEDICINES
HEALTH
24 October 2013
EMA/699150/2013
Committee for Medicinal Products for Human Use (CHMP)
Brintellix
vortioxetine
Procedure No. EMEA/H/C/002717
Applicant: H. Lundbeck A/S
Assessment report for an initial marketing authorisation application
Assessment report as adopted by the CHMP with
all commercially confidential information deleted
7 Westferry Circus . Canary Wharf . London E14 4HB . United Kingdom
Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416
E-mail info@ema.europa.eu Website www.ema.europa.eu
An agency of the European Union
European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged.
Table of contents
1. Background information on the procedure
6
1.1. Submission of the dossier
6
7
1.2. Manufacturers.
1.3. Steps taken for the assessment of the product.
7
2. Scientific discussion
8
2.1. Introduction.
8
2.2. Quality aspects
9
2.2.1. Introduction
9
2.2.2. Active Substance
10
2.2.3. Finished Medicinal Product
12
2.2.4. Discussion on chemical, pharmaceutical and biological aspects
15
2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects
15
2.3. Non-clinical aspects
15
2.3.1. Introduction
15
2.3.2. Pharmacology
16
2.3.3. Pharmacokinetics.
19
2.3.4. Toxicology
20
2.3.5. Ecotoxicity/environmental risk assessment
27
2.3.6. Discussion on non-clinical aspects.
29
2.3.7. Conclusion on the non-clinical aspects
30
2.4. Clinical aspects
30
2.4.1. Introduction
30
2.4.2. Pharmacokinetics
34
2.4.3. Pharmacodynamics
44
2.4.4. Discussion on clinical pharmacology .
45
2.4.5. Conclusions on clinical pharmacology
46
2.5. Clinical efficacy
47
2.5.1. Dose response studies.
47
2.5.2. Main studies
47
2.5.3. Discussion on clinical efficacy
110
2.5.4. Conclusions on clinical efficacy
121
2.6. Clinical safety
125
2.6.1. Discussion on clinical safety
146
2.6.2. Conclusions on the clinical safety
150
2.7. Pharmacovigilance.
150
2.8. Risk Management Plan
150
2.9. User consultation
154
3. Benefit-Risk Balance.
Benefits
154
154
Beneficial effects
154
Uncertainty in the knowledge about the beneficial effects
155
Risks
156
Unfavourable effects
156
Brintellix
EMA/699150/2013
Page 2/159
